Radiofrequency Ablation (RFA) has become a well-recognized non-pharmacological treatment strategy for many cardiac arrhythmias (1) because of a high success rate and low risk of complications. RFA is recommended as first-line therapy in patients with paroxysmal or persistent AF with minimal structural heart disease (2). Atrial Fibrillation (AFib) is the most common chronic rhythm disorder encountered in clinical practice (3). Besides being often symptomatic due to high ventricular rates, it is responsible for functional limitation and cardiomyopathy induced by tachycardia (4). In 1996, the Bordeaux group (3) noted that AFib is initiated by rapidly firing triggers located in the pulmonary veins. Pulmonary vein isolation (PVI) via catheter ablation via femoral approach is a widely applied technique.